Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix

"Degarelix (Firmagon®) will be administered as a subcutaneous injection in the abdominal region every 28 days, in according to the following schedule:~* Starting dose: 240 mg administered as two consecutive subcutaneous injections of 120 mg each (2 x 3 mL injections).~* Maintenance dose: 80 mg administered as one subcutaneous injection of 80 mg (1 x 4 mL injection).~Treatment will be continued till clinically indicated or till disease progression."